gemfibrozil and rifampin

gemfibrozil has been researched along with rifampin in 24 studies

Research

Studies (24)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (16.67)	29.6817
2010's	17 (70.83)	24.3611
2020's	3 (12.50)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Backman, JT; Luurila, H; Neuvonen, M; Neuvonen, PJ	1
Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ	1
Bergman, A; Feng, B; Goosen, TC; Lai, Y; Litchfield, J; Varma, MV	1
Broedl, UC; Hummel, N; Koenen, R; Macha, S; Riedmaier, S; Salsali, A; Schöne, K; Sennewald, R; Woerle, HJ	1
Izumi, S; Komori, T; Kusuhara, H; Maeda, K; Nozaki, Y; Sugiyama, Y; Takenaka, O	1
Bi, Y; El-Kattan, AF; Eng, H; Kalgutkar, AS; Kimoto, E; Lin, J; Rodrigues, AD; Scialis, R; Tremaine, LM; Varma, MV	1
Leil, T; Wang, Q; Zheng, M	1
Boehler, M; Bruderer, S; Dingemanse, J; Halabi, A; Petersen-Sylla, M; Remeňová, T	1
Chen, EC; Chen, Y; Choo, EF; Liu, L; Ma, F; Mao, J; Sahasranaman, S; Zhu, R	1
Dorer, DJ; Gupta, N; Hanley, MJ; Kerstein, D; Narasimhan, N; Sonnichsen, D; Tugnait, M; Venkatakrishnan, K	1
Ghosh, A; Liu, L; Palmisano, M; Syto, M; Tran, JQ; Wang, X; Zhang, P	1
Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L	1

Reviews

1 review(s) available for gemfibrozil and rifampin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

5 trial(s) available for gemfibrozil and rifampin

Article	Year
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:2 Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrroles; Rifampin	2005
Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clinical therapeutics, 2014, Feb-01, Volume: 36, Issue:2 Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Glucosides; Humans; Male; Middle Aged; Probenecid; Rifampin; Sodium-Glucose Transporter 2 Inhibitors	2014
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. British journal of clinical pharmacology, 2017, Volume: 83, Issue:12 Topics: Acetamides; Acetates; Activation, Metabolic; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Gemfibrozil; Germany; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Pyrazines; Rifampin; Risk Assessment; Young Adult	2017
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical pharmacology in drug development, 2020, Volume: 9, Issue:2 Topics: Administration, Oral; Adult; Aged; Anaplastic Lymphoma Kinase; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrimidines; Rifampin	2020
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. Advances in therapy, 2020, Volume: 37, Issue:10 Topics: Area Under Curve; Cross-Over Studies; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Indans; Itraconazole; Oxadiazoles; Rifampin	2020

Other Studies

18 other study(ies) available for gemfibrozil and rifampin

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:8 Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic & clinical pharmacology & toxicology, 2005, Volume: 97, Issue:4 Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin	2005
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharmaceutical research, 2012, Volume: 29, Issue:10 Topics: Adolescent; Adult; Aged; Area Under Curve; Biological Transport; Cells, Cultured; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Rifampin; Young Adult	2012
Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:2 Topics: Antihypertensive Agents; Binding, Competitive; Biological Transport; Cyclohexanes; Cyclosporine; Drug Evaluation, Preclinical; Drug Interactions; Estradiol; Gemfibrozil; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kinetics; Liver-Specific Organic Anion Transporter 1; Membrane Transport Modulators; Models, Biological; Nateglinide; Organic Anion Transporters; Phenylalanine; Recombinant Proteins; Rifampin; Sulfonamides; Torsemide	2015
Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. Clinical pharmacology and therapeutics, 2017, Volume: 101, Issue:3 Topics: Acetates; Animals; Clarithromycin; Cyclopropanes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Gemfibrozil; Haplorhini; Hepatocytes; Liver; Liver-Specific Organic Anion Transporter 1; Models, Biological; Nucleic Acid Synthesis Inhibitors; Organic Anion Transporters; Quinolines; Rats; Rifampin; Sulfides	2017
Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. CPT: pharmacometrics & systems pharmacology, 2017, Volume: 6, Issue:4 Topics: Administration, Intravenous; Administration, Oral; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Gemfibrozil; Gene Expression Regulation; Humans; Liver-Specific Organic Anion Transporter 1; Models, Theoretical; Neoplasm Proteins; Organic Anion Transporters, Sodium-Independent; Rifampin; Rosuvastatin Calcium; Solute Carrier Organic Anion Transporter Family Member 1B3	2017
Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. Biopharmaceutics & drug disposition, 2018, Volume: 39, Issue:9 Topics: Area Under Curve; Cinnamates; Cyclosporine; Drug Interactions; Gemfibrozil; Humans; Indazoles; Liver-Specific Organic Anion Transporter 1; Models, Biological; Pravastatin; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3	2018
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers. Clinical pharmacokinetics, 2022, Volume: 61, Issue:10 Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide	2022